Skip to main content
Category

News Archive

COVID 19 Patients Exhibit Early Antibody Signatures Potentially Predictive of Death or Recovery

COVID-19 Patients Exhibit Early Antibody Signatures Potentially Predictive of Death or Recovery

By News Archive

COVID 19 Patients Exhibit Early Antibody Signatures Potentially Predictive of Death or Recovery

Researchers at the Ragon Institute of MGH, MIT and Harvard, and the University of Washington (UW) School of Medicine, have identified five immune response markers that, collectively, were able to distinguish between those COVID-19 patients who convalesced from the infection, and those who didn’t survive the disease. The researchers used a systems serology technique to generate a detailed profile of SARS-Co-2-specific humoral—antibody generating—responses in hospitalized patients, which they validated in a second patient cohort. The findings indicated that individuals who survived COVID-19 infection and those who died exhibited antibody responses that were primarily directed against different SARS-CoV-2 proteins.

Image: NIH

Read More
NewImage

SHYCOCAN – A Device to Disable Coronaviruses – to be Marketed Under US-FDA’s Enforcement Discretion During the COVID-19 Public Health Emergency

By News Archive

NewImage

GAITHERSBURG, Md., July 23, 2020 /PRNewswire/ — Shreis Scalene Therapeutics LLC (SSTx), a MD-USA-based medical device company will fast-track the manufacture and distribution of the CE-marked (EU-Class 1) Scalene Hypercharge Corona Canon (SHYCOCAN) under US FDA ‘Enforcement Policy for Sterilizers, Disinfectant Devices, and Air Purifiers During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.”

Image: SHYCOCAN Devices

Read More
Alexandria Logo

This Company is the Landlord of Life Sciences | InvestorPlace

By News Archive

Alexandria Logo

With so much attention on COVID-19 treatment and vaccine developments, life science laboratories are getting more notice.

Alexandria Real Estate Equities (NYSE:ARE) is a real estate investment trust (REIT) based in Pasadena, California. It’s the largest landlord in the US for laboratories and related offices.

Its top companies by rent revenues include Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY), Celgene, Eli Lilly (NYSE:LLY), Merck (NYSE:MRK)—which we own in Profitable Investing—Moderna (NASDAQ:MRNA), Novartis (NYSE:NVS), Pfizer (NYSE:PFE) and Sanofi (NASDAQ:SNY).

 

Read More
NewImage

Race for coronavirus vaccine takes big step with trial at University of Maryland – Baltimore Sun

By News Archive

NewImage

The University of Maryland School of Medicine and about 30 other U.S. centers have begun recruiting thousands of volunteers living in COVID-19 hot spots to join the nation’s most advanced trial for a vaccine against the disease.

The vaccine was developed by the Massachusetts biotech company Moderna along with the National Institutes of Health. It is among several vaccines to reach a Phase 3 trial globally but was the first one announced under Operation Warp Speed, the federal program to quickly identify, produce and distribute 300 million doses of a COVID-19 vaccine.

Read More
Novavax Logo

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan Nasdaq:NVAX

By News Archive

Novavax Logo

GAITHERSBURG, Md. and OSAKA, Japan, Aug. 07, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. Takeda will receive funding from the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) to support the technology transfer, establishment of infrastructure and scale-up of manufacturing. Takeda anticipates the capacity to manufacture over 250 million doses of the COVID-19 vaccine per year1.

 

Read More
Emmes Promotes Three VPs to Officer Positions State heraldmailmedia com

Emmes Promotes Three VPs to Officer Positions | State | heraldmailmedia.com

By News Archive

Emmes Promotes Three VPs to Officer Positions State heraldmailmedia com

ROCKVILLE, Md., Aug. 6, 2020 /PRNewswire/ — Emmes today announced that three corporate vice presidents have been promoted. Dr. Traci Clemons has been named chief research officer, Marian Ewell is now chief scientific innovation officer, and Jennifer Hester is the company’s chief human resources officer. These are all newly created positions for the company.

Image: Dr. Traci Clemons

Read More
Face to Face with Chancellor Perman UMB News

Face to Face with Chancellor Perman – UMB News

By News Archive

Face to Face with Chancellor Perman UMB News

The year 2020 began with great promise and opportunity for the Aug. 6 guest of the weekly web-based program, Virtual Face to Face with Dr. Bruce Jarrell. After tearful goodbyes here at the University of Maryland, Baltimore (UMB), the University System of Maryland (USM) embraced former president Jay A. Perman, MD, as its new chancellor on Jan. 6.

Image: https://www.umaryland.edu

Read More
Johns Hopkins moves to virtual learning for fall tells students not to return to Baltimore TheHill

Johns Hopkins moves to virtual learning for fall, tells students not to return to Baltimore | TheHill

By News Archive

Johns Hopkins moves to virtual learning for fall tells students not to return to Baltimore TheHill

Johns Hopkins University became the latest school to announce that it will be conducting classes for the upcoming fall semester virtually, one of the many institutions of higher education to forgo in-person learning as the coronavirus pandemic rages.

This follows the spring 2020 semester that was moved online during the onset of the virus. 

Image: https://thehill.com

Read More
GSK

GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults | News | wfmz.com

By News Archive

GSK

PHILADELPHIA, Aug. 5, 2020 /PRNewswire/ — GSK today launched a national campaign to help increase low rates of vaccination among older adults. The campaign, Brought to You By Vaccines, will educate adults ages 50 and older about the value of vaccines and the urgent need to talk to their healthcare provider or pharmacist about the recommended vaccines they need or may have recently missed.

 

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.